In mouse models of psoriasis, clock gene mutations changed skin inflammation by modulating IL-23 receptor expression in gamma delta T cells and subsequent IL-17 and IL-22 production (271) and treatment with a REVERB agonist suppressed IL-17 production in gamma-delta T cells and improved dermatitis (199). Here, IL17A is linked to psoriasis.